Real-World Comparative Effectiveness of Albumin-Bound Paclitaxel Plus Carboplatin Versus Solvent-Based Paclitaxel Plus Carboplatin

Poster Presentation at NCCN 21st Annual Conference

Background: In a subset analysis of a multinational phase III randomized clinical trial (RCT), weekly albumin-bound paclitaxel + carboplatin (nabP/C) demonstrated a higher response rate (41% vs 24%; P<.01) than solvent-based paclitaxel + carboplatin (sb-P/C) every 3 weeks, with less grade ≥3 neuropathy and arthralgia, but more thrombocytopenia and anemia in patients with advanced squamous cell carcinoma (SCC) non–small cell lung cancer (NSCLC) (Socinski MA, et al. J Clin Oncol 2012). NCCN Guidelines support the use of nab-P/C, but there is limited published experience with this combination in real-world settings. 

Authors: Stuart L. Goldberg, MD; Harry D. Harper, MD; Manish B. Patel, PharmD; Claudio Faria, PharmD, MPH; Tommy Wu, BS; Samira Daswani, BS; Eric Schultz; and Kelly Choi, MD

Thank you signing up!
Oops! Something went wrong while submitting the form

Digital characterization of breast cancer phenotypes to identify variances in care and costs at scale

This study applies the novel Cota Nodal Address (CNA) digital system to a consecutive cohort of patients with breast cancer to identify population frequencies of subtypes and variances in treatment patterns and total costs of care for one year following diagnosis.
March 16, 2017
Research Abstract

Prevalence of clinically meaningful prognostic variability in cancer: An analysis using a new taxonomy system

Precise characterizations of tumor type to permit “precision” medicine are required for optimal outcomes and to facilitate payment reforms. ICD9 codes lump multiple cancer subtypes together (eg: all lung cancers ICD9 162.x). To enable comparisons of similar tumor types a new taxonomy system, amenable to computerized searching, has been created that embraces the complexity of cancer.
March 16, 2017
Research Abstract

A new digital classification schema to detect treatment variances and enable value based payment reforms

Value based payment reforms which improve the outcome to cost ratio (paying for outcomes not for services) require detailed information on both elements. Although the digitalization of medicine via the EHR may facilitate data collection, the imprecise ICD9 and ICD10 schemas hinder analysis (eg: all breast cancers are ICD9 174.9). A more precise classification schema that accounts for biologic variances to allow analysis (and reduction) of treatment variances is needed.
March 16, 2017
Research Abstract